News Archive - InnoSIGN

Filters

The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy

InnoSIGN welcomes Mark Oldroyd as Board Member

InnoSIGN aims to increase survival rates of cancer patients using PCR tests

InnoSIGN wins Gerard & Anton Award

High HH and low AR associated with resistance to ARDT in prostate cancer

$9.2 M raised during Series A investment round

InnoSIGN is developing a smart PCR test to predict which drug will work in a cancer patient

Interview with Sr. Investment Manager BOM and CEO InnoSIGN

PCR test predicts which medication will best work

InnoSIGN completes spin-out from Philips, $8M Series A

Signaling pathways in high-grade serous ovarian carcinoma